Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
- First Posted Date
- 2004-04-02
- Last Posted Date
- 2013-05-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT00006368
- Locations
- ๐บ๐ธ
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2004-04-02
- Last Posted Date
- 2013-05-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 275
- Registration Number
- NCT00006370
- Locations
- ๐บ๐ธ
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma
- First Posted Date
- 2004-03-22
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 628
- Registration Number
- NCT00079937
- Locations
- ๐บ๐ธ
Clinical Research Institute of Southern Oregon, Medford, Oregon, United States
๐บ๐ธFamily Allergy and Asthma Center, PC, Atlanta, Georgia, United States
๐บ๐ธWest Penn Allegheny General Health System, Pittsburgh, Pennsylvania, United States
Pediatric Hypothalamic Obesity
- Conditions
- First Posted Date
- 2004-01-23
- Last Posted Date
- 2011-09-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT00076362
- Locations
- ๐บ๐ธ
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
๐บ๐ธUniversity of Colorado, Denver, Colorado, United States
๐บ๐ธUniversity of California at San Francisco, San Francisco, California, United States
Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2004-01-22
- Last Posted Date
- 2011-09-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 232
- Registration Number
- NCT00076336
- Locations
- ๐ป๐ณ
Novartis, Hanoi, Vietnam
Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer
- First Posted Date
- 2003-11-26
- Last Posted Date
- 2021-02-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1286
- Registration Number
- NCT00073528
- Locations
- ๐ฌ๐ง
Novartis Investigative Site, Sheffield, United Kingdom
Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)
- Conditions
- First Posted Date
- 2003-11-11
- Last Posted Date
- 2011-11-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 551
- Registration Number
- NCT00072709
- Locations
- ๐บ๐ธ
Novartis USA, East Hanover, New Jersey, United States
๐ง๐ชNovartis Belgium, Vilvoorde, Belgium
๐จ๐ญNovartis Switzerland, Bern, Switzerland
Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions
- First Posted Date
- 2003-08-13
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 195
- Registration Number
- NCT00067080
- Locations
- ๐บ๐ธ
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
๐บ๐ธJames Cancer Hospital, Columbus, Ohio, United States
๐บ๐ธChildren's Hospital Boston, Division of Hematology/Oncology, Boston, Massachusetts, United States
The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
- Conditions
- First Posted Date
- 2003-07-03
- Last Posted Date
- 2017-09-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT00063609
- Locations
- ๐บ๐ธ
Southeastern Urological Center, PA, Tallahassee, Florida, United States
๐บ๐ธAdvanced Urology Med. Center, Anaheim, California, United States
๐บ๐ธGrove Hill Urology, New Britain, Connecticut, United States
Bisphosphonate Treatment of Osteogenesis Imperfecta
- Conditions
- First Posted Date
- 2003-06-30
- Last Posted Date
- 2017-06-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 158
- Registration Number
- NCT00063479
- Locations
- ๐บ๐ธ
Children's Hospital Medical Center, Cincinnati, Ohio, United States
๐บ๐ธUCLA - Division of Pediatric Nephrology, Los Angeles, California, United States
๐บ๐ธTexas Children's Hosptial, Houston, Texas, United States